Advanced oral delivery of peptides and peptidomimetics presents complex challenges due to their susceptibility to digestion and poor permeability through the intestinal cell layer. In most cases, the inherent oral bioavailability of peptides is nonexistent without an enabling technology.
Peptelligence® uniquely overcomes these barriers by deploying an innovative combination of formulation methods and excipients which synergistically enhance permeation and protect the peptides from being digested. Unlike other technologies, Peptelligence improves oral bioavailability through a smart combination of pH-lowering, charge dispersal, membrane wetting, and solubilizing agents in a highly scalable solid oral dosage form without making physicochemical modifications to the API. The technology is not a one-size-fits all, but rather we work collaboratively with our partners to develop customized and optimized formulations for their specific API, while also providing robust IP protection.
Enteris has demonstrated positive results in numerous feasibility studies and clinical trials and with a myriad of peptide modalities. As a true full-service partner of choice, Enteris BioPharma is uniquely qualified to provide total integrated oral peptide product development from the earliest stages of research through late-stage clinical trials and commercial manufacturing.
